Emblaveo (aztreonam/avibactam) / Pfizer, AstraZeneca, AbbVie - LARVOL DELTA

Comparative in vitro activity of aztreonam-avibactam and aztreonam plus ceftazidime-avibactam against Stenotrophomonas maltophilia complex. (PubMed, Antimicrob Agents Chemother) - "ATM-AVI and ATM-CZA show comparable in vitro activity against S. maltophilia complex. Isolate-level heterogeneity warrants further study of genotype-phenotype relationships."

Journal • Preclinical

Clinical and genomic determinants associated with emergent ceftazidime-avibactam plus aztreonam non-susceptibility in ceftazidime-avibactam resistant Escherichia coli. (PubMed, Antimicrob Agents Chemother) - "We performed a comprehensive clinical and genomic analysis of ceftazidime-avibactam-resistant Escherichia coli (CZA-R-Ec) collected at a tertiary cancer center (2017-2024) to identify patient- and isolate-level factors associated with reduced susceptibility to ATM/CZA and aztreonam-avibactam (AZA). In conclusion, CZA-R-Ec at our center are dominated by PBP3-insertion, blaNDM-5-positive lineages, for which ATM/CZA retains substantial in vitro activity and clinical efficacy. However, prior E. coli infection and blaCMY-42 variant positivity identify patients at risk for ATM/CZA non-susceptible infections."

Journal • Infectious Disease • Oncology

Outstanding presence of New Delhi metallo-beta-lactamase in carbapenem-resistant Enterobacterales and exceptionally potent in vitro activity of cefiderocol and aztreonam-avibactam emphasises their immediate access in India. (PubMed, Trans R Soc Trop Med Hyg) - "Our study showed an exceptionally high prevalence of the blaNDM gene among CRE clinical isolates. Either aztreonam-avibactam or cefiderocol was found to be effective against 98% of CRE isolates highlighting the immediate need of making these two drugs accessible to patients in India."

Journal • Preclinical • Infectious Disease

Real-World Evidence and Multidrug Resistant Infections: How Can We Leverage RWE to Improve Patient Outcome with the Novel Beta-Lactam and Beta-Lactam/Beta-Lactamase Inhibitor Combinations. (PubMed, Infect Drug Resist) - "A comprehensive literature search was performed on PubMed-MEDLINE from January 2015 to September 2025 for identifying pivotal trials and real-world evidence concerning the use of cefiderocol and of novel beta-lactam/beta-lactamase inhibitor combination (BL/BLIc) including those of tomorrow (ie, ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, cefepime-enmetazobactam, cefepime-taniborbactam, cefepime-zidebactam, sulbactam-durlobactam, aztreonam-avibactam). Real-world evidence concerning both well-designed observational studies and PK/PD models may represent a mandatory tool for overcoming issues associated with pivotal trials evaluating novel BL/BLIc. The implementation of dedicated well-designed real-world studies would be warranted for ensuring a constant update of proposed therapeutic algorithms."

HEOR • Journal • Real-world evidence • Review • Infectious Disease

AWARE: Real-World Effectiveness of Aztreonam-Avibactam Against MBL-Producing CRE (clinicaltrials.gov) - P=N/A | N=100 | Recruiting | Sponsor: Sir Run Run Shaw Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Real-world evidence • Infectious Disease • Pneumonia • Respiratory Diseases

IS06 - Optimising management of MDR Gram-negative bacterial infections, including MBL producers (ESCMID Global 2026) - "Our expert faculty will explore how ATM-AVI, a ?-lactam/?-lactamase inhibitor combination active against MBL-producing Enterobacterales and Stenotrophomonas maltophilia infections,4-7 has been optimised to treat these infections, through a review of its pharmacokinetics/pharmacodynamics and in vitro and clinical efficacy and safety data. Finally, we will move beyond theory, with interactive clinical scenarios to demonstrate early warning signs that should trigger suspicion of MDR Gram-negative bacterial infections, timing for optimal treatment initiation, and strategies for managing challenging patient populations."

Gram negative • Infectious Disease

Activity of cefiderocol/xeruborbactam against NDM-producing Escherichia coli isolates with PBP3 insertions and decreased susceptibility or resistance to aztreonam/avibactam, cefiderocol, and cefepime/taniborbactam (ESCMID Global 2026) - No abstract available

Optimising antibiotic therapy through PK-PD: a deep dive into ATM-AVI (ESCMID Global 2026) - "Organised by Pfizer"

PK/PD data

IPT24 - Optimising antibiotic therapy through PK-PD: a deep dive into ATM-AVI (ESCMID Global 2026) - "Organised by Pfizer"

PK/PD data

From bench to bedside: how ATM-AVI redefines treatment for CR pathogens, including MBL producers in China (ESCMID Global 2026) - "Organised by Pfizer"

IPT15 - From bench to bedside: how ATM-AVI redefines treatment for CR pathogens, including MBL producers in China (ESCMID Global 2026) - "Organised by Pfizer"

Precision dosing and therapeutic drug monitoring of aztreonam/avibactam in a liver transplant recipient with CRKP infection and acute kidney injury (ESCMID Global 2026) - No abstract available

Clinical • Acute Kidney Injury • Infectious Disease • Nephrology • Renal Disease • Transplantation

When in vitro meets in vivo: therapeutic role of ceftazidime/avibactam & aztreonam in metallo-β-lactamase-producing, colistin-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa: a five-case translational experience (ESCMID Global 2026) - No abstract available

Preclinical • Infectious Disease • Pneumonia

Case Report: aztreonam-avibactam for bloodstream infection caused by metallo-β-lactamase-producing carbapenem-resistant Klebsiella pneumoniae after allogeneic haematopoietic stem cell transplantation (ESCMID Global 2026) - No abstract available

Case report • Clinical • Infectious Disease • Pneumonia • Transplantation

?Aztreonam/avibactam as treatment for VIM-producing carbapenem-resistant Klebsiella pneumoniae complicated urinary tract infection in an elderly patient: a case report (ESCMID Global 2026) - No abstract available

Case report • Clinical • Infectious Disease • Nephrology • Pneumonia

Rapid microbiological and genomic clearance of MBL-CRE pneumonia following tNGS-guided aztreonam/avibactam therapy in a 93-year-old patient (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease • Pneumonia • Respiratory Diseases

Case report: treatment of intracranial CRE Klebsiella pneumoniae infection following surgery of intracerebral haemorrhage with aztreonam/avibactam (ESCMID Global 2026) - No abstract available

Case report • Clinical • Surgery • Infectious Disease • Pneumonia

Successful treatment of sequential pulmonary and bloodstream infections caused by Stenotrophomonas maltophilia with aztreonam/avibactam: a case report (ESCMID Global 2026) - No abstract available

Case report • Clinical • Infectious Disease

NDM Escherichia coli with aztreonam/avibactam and/or cefiderocol resistance in immunocompromised paediatric patients and use of cefepime/zidebactam (ESCMID Global 2026) - No abstract available

Clinical • Pediatrics

SY160 - Emerging resistance to new antibiotics: are we already losing the newest tools? (ESCMID Global 2026) - "This session explores the troubling rise of resistance to recently approved antibiotics, including cefiderocol, ceftazidime-avibactam, imipenem/relebactam, cefepime-taniborbactam, aztreonam-avibactam, etc. Although these drugs were introduced as critical last-resort options against multidrug-resistant infections, reports of resistance have emerged within just a few years of clinical use. The panel will address the urgent need for improved stewardship, faster diagnostics, and equitable access to new antibiotics to preserve their effectiveness. Participants will gain insights into how resistance spreads, how policies impact antimicrobial use, and what strategies might still help us stay ahead in the race against resistant pathogens."

Infectious Disease

In vitro activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales isolated from urine samples (ESCMID Global 2026) - No abstract available

Preclinical

Broad-spectrum in vitro activity of ceftazidime/avibactam/aztreonam against Klebsiella pneumoniae with diverse resistance mechanisms (ESCMID Global 2026) - No abstract available

Preclinical • Infectious Disease • Pneumonia

The in vitro activity of aztreonam/avibactam and cefiderocol against Escherichia coli isolates that carry insertions in penicillin-binding protein 3 (PBP3) with and without acquired AmpC as a part of the ATLAS global surveillance program, 2024 (ESCMID Global 2026) - No abstract available

Preclinical

In vitro activity of aztreonam/avibactam and distribution of carbapenemase genes in ceftazidime/avibactam-resistant carbapenem-resistant Enterobacterales: data from the global antimicrobial testing leadership and surveillance, 2019–2023 (ESCMID Global 2026) - No abstract available

Preclinical

The in vitro activity of aztreonam/nacubactam and cefepime/nacubactam against molecularly characterised Enterobacterales isolates including those with ceftazidime-avibactam and aztreonam/avibactam resistance mechanisms collected globally from 2021-2023 (ESCMID Global 2026) - No abstract available

Preclinical